出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2024年1月
Tissue Diagnostics Market – Global Forecast to 2028
組織診断市場 : 製品［消耗品（抗体、試薬、組織、プローブ）、機器（処理システム、スキャナー）］、テクノロジー（ISH、IHC、スライド染色）、疾患タイプ（乳がん、リンパ腫、前立腺がん） – 2028年までの世界予測
Tissue Diagnostics Market by Product (Consumables (Antibodies, Reagents, Tissue, Probes), Instrument (Processing System, Scanner)), Technology (ISH, IHC, Slide Staining), Disease Type (Breast Cancer, Lymphoma, Prostate Cancer) – Global Forecast to 2028
| ページ数 | 254 |
| 図表数 | 231 |
| 種別 | 英文調査報告書 |
| 価格 |
Report Overview
The global tissue diagnostics market is projected to reach USD 8.4 billion by 2028 from USD 5.6 billion in 2023, at a CAGR of 8.4% during the forecast period. Market growth is driven by factors such as the rising prevalence of cancer, increasing availability of reimbursements and increasing technological advancements in tissue diagnostics are the major factors driving the growth of the market.
“The Consumables to register the largest share of the tissue diagnostics market, by product.”
The global tissue diagnostics market product segment is divided into Consumables and Instruments . In product segment the consumables is expected to account for the largest share of the tissue diagnostics market in 2022. Market growth is largely driven by the rise in government and private funding in life sciences and cancer research, growing R&D expenditure by leading pharma companies. Moreover, the availability of better consumables that offer efficient results and precision in diagnosis attributes to their growing demand, resulting in growth of the segment.
“Immunohistochemistry tissue diagnostics segment to grow at a considerable rate among technology during the forecast period.”
The tissue diagnostics market is four technology segments, namely, Immunohistochemistry (IHC), In Situ Hybridization (ISH), Digital Pathology & Workflow, and Special Staining. The Immunohistochemistry technology segment is expected to account for the largest share of the tissue diagnostics market in 2022. The large share of this segment can primarily be attributed to the Rising geriatric population and growing prevalence of cancer diseases diabetes, availability of reimbursements for IHC tests, and adoption of digital pathology are driving the demand for immunohistochemistry products.
“Breast Cancer segment accounted for the largest share in the tissue diagnostics market, by disease.”
The global tissue diagnostics market is segmented into Breast Cancer, Gastric Cancer, Lymphoma, Prostate Cancer, Non-small Cell Lung Cancer, and Other Diseases. The breast cancer segment accounted for a largest share in 2022, primarily due number of factors such as age, family history, reproductive history, the presence of dense breast tissues, a lack of physical activity, alcohol consumption, smoking, radiation exposure coupled with the increasing incidence of breast cancer such as ductal carcinoma in situ (DCIS), invasive ductal carcinoma (IDC), and inflammatory breast cancer (IBC), among others.
“Asia Pacific: The fastest-growing region in the tissue diagnostics market.”
The global tissue diagnostics market is segmented into four major regions – North America, Europe, the Asia Pacific, and Rest of the World (RoW). The Asia Pacific region is expected to grow at the highest rate in the tissue diagnostics market during the forecast period. The high growth in the region is due to the presence of a large target population, the economic growth in the countries of this region and rising prevalence of cancer in Asian countries.
The break-up of the profile of primary participants in the tissue diagnostics market:
• By Company Type: Tier 1 – 40%, Tier 2 – 30%, and Tier 3 – 30%
• By Designation: C-level – 27%, D-level – 18%, and Others – 55%
• By Region: North America – 51%, Europe – 21%, Asia Pacific – 18%, and Rest of the World- 10%
The key players in this market are F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (US), PHC Holdings Corporation Corporation (Japan), Agilent Technologies Inc. (US), Thermo Fisher Scientific, Inc (US), Abbott (US), Merck KGAA (Germany), SAKURA FINETEK JAPAN CO., LTD (Japan), Abcam Plc. (UK), Becton, Dickinson and Company (BD) (US), Bio SB (US), Biogenix (US), Cell Signaling Technology, Inc (US), Histo-Line Laboratories (Italy), SLEE Medical GMBH (Germany), Cellpath Ltd (UK), Amos scientific Pty Ltd. (Australia), Jinhua YIDI Medical Appliance CO.,LTD (China), MEDITE Medical GmbH (Germany), Diapath S.p.A. (Italy), KONFOONG BIOINFORMATION TECH CO.,LTD (China), Diagnostic BioSystems Inc. (US), 3DHISTECH (Hungary), RWD Life Science Co.,LTD (China), Dakewei Biotechnology co., Ltd (China), Sysmax Corporation (Japan), Enzo Life Sciences, Inc. (US), Biocare Medical, LLC. (US), MILESTONE MEDICAL (US), and Bio-Optica Milano Spa (Italy).
Research Coverage:
This research report categorizes the tissue diagnostics market by product (consumables and instruments), technology (immunohistochemistry (IHC), in situ hybridization (ISH), digital pathology & workflow management, special staining), disease type (breast cancer, gastric cancer, lymphoma, prostate cancer, non-small cell lung cancer, other disease types), end user (hospitals, research laboratories, pharmaceutical companies, Contract Research Organizations (CROs), and Other End Users), and region (North America, Europe, Asia Pacific, and Rest of the World). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges, influencing the growth of the tissue diangostics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products offered, key strategies, acquisitions, and partnerships. New product launches and approvals, and recent developments associated with the tissue diagnostics market. This report covers the competitive analysis of upcoming startups in the tissue diangostics market ecosystem.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall tissue diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
• Analysis of key drivers (the rising prevalence of cancer, growing healthcare expenditure, growing demand for digital pathology, increasing healthcare expenditure, developing infrastructure for cancer diagnosis, increasing availability of reimbursements, and increasing technological advancements in tissue diagnostics are the major factors driving the growth of the market), restraints (high degree of consolidation, high cost of diagnostic imaging system), opportunities (significant opportunities in BRICS countries, growing demand for personalized medicines, increasing number of clinical trails perraining to cancer drugs, emerging economics to offer significant opportunities to companies), challenges (lack of skilled professionals, availability of refurbished products, stringent regulatory requirements, lack of infrastructure and low awareness in middle and low income countries and lack of standardization ) and trends (Increasing number of reagent rental agreements, increasing usage of Al in histopathology ) influencing the growth of the tissue diagnostics market
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the tissue diagnostics market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the tissue diagnostics market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the tissue diagnostics market
• Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players like F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (US), PHC Holdings Corporation (Japan), Agilent Technologies (US), Thermo Fisher Scientific Inc. (US), and among others in the tissue diagnostics market strategies.
Table of Contents
1 INTRODUCTION 31
1.1 STUDY OBJECTIVES 31
1.2 MARKET DEFINITION 31
1.3 INCLUSIONS AND EXCLUSIONS 32
1.4 MARKET SCOPE 33
1.4.1 MARKETS COVERED 33
FIGURE 1 MARKET SEGMENTATION 33
1.4.2 REGIONS COVERED 33
1.4.3 YEARS CONSIDERED 34
1.4.4 CURRENCY CONSIDERED 34
1.5 STAKEHOLDERS 34
1.6 SUMMARY OF CHANGES 35
2 RESEARCH METHODOLOGY 36
2.1 RESEARCH DATA 36
FIGURE 2 RESEARCH DESIGN 36
2.1.1 SECONDARY RESEARCH 37
2.1.1.1 Key data from secondary sources 38
2.1.2 PRIMARY RESEARCH 38
2.1.2.1 Primary sources 39
2.1.2.2 Key data from primary sources 39
2.1.2.3 Key industry insights 41
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 41
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 42
2.2 MARKET SIZE ESTIMATION 42
2.2.1 BOTTOM-UP APPROACH 43
FIGURE 5 REVENUE SHARE ANALYSIS 43
FIGURE 6 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS 44
FIGURE 7 TISSUE DIAGNOSTICS MARKET: TOP-DOWN APPROACH 45
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 46
FIGURE 8 DATA TRIANGULATION METHODOLOGY 46
2.4 MARKET SHARE ANALYSIS 47
2.5 STUDY ASSUMPTIONS 47
2.5.1 MARKET ASSUMPTIONS 47
2.5.2 GROWTH RATE ASSUMPTIONS 47
2.6 RESEARCH LIMITATIONS 48
2.6.1 METHODOLOGY-RELATED LIMITATIONS 48
2.6.2 SCOPE-RELATED LIMITATIONS 48
2.7 RISK ASSESSMENT 48
TABLE 1 RISK ASSESSMENT ANALYSIS 48
2.8 RECESSION IMPACT ANALYSIS 48
3 EXECUTIVE SUMMARY 49
FIGURE 9 TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2023 VS. 2028 (USD BILLION) 49
FIGURE 10 TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD BILLION) 50
FIGURE 11 TISSUE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023 VS. 2028 (USD BILLION) 50
FIGURE 12 TISSUE DIAGNOSTICS MARKET, BY END USER, 2023 VS. 2028 (USD BILLION) 51
FIGURE 13 GEOGRAPHICAL SNAPSHOT OF TISSUE DIAGNOSTICS MARKET 52
4 PREMIUM INSIGHTS 53
4.1 TISSUE DIAGNOSTICS MARKET OVERVIEW 53
FIGURE 14 RISING INCIDENCE OF CANCER AND INFECTIOUS DISEASES TO DRIVE MARKET GROWTH DURING FORECAST PERIOD 53
4.2 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & COUNTRY (2022) 54
FIGURE 15 CONSUMABLES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 54
4.3 TISSUE DIAGNOSTICS MARKET: GEOGRAPHICAL SNAPSHOT 54
FIGURE 16 CHINA & INDIA TO WITNESS HIGHEST GROWTH RATE DURING FORECAST PERIOD 54
4.4 TISSUE DIAGNOSTICS MARKET: REGIONAL MIX 55
FIGURE 17 ASIA PACIFIC REGION IS PROJECTED TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD 55
4.5 TISSUE DIAGNOSTICS MARKET: DEVELOPED COUNTRIES VS. EMERGING ECONOMIES 55
FIGURE 18 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD 55
5 MARKET OVERVIEW 56
5.1 INTRODUCTION 56
5.2 MARKET DYNAMICS 56
FIGURE 19 TISSUE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 56
5.2.1 DRIVERS 57
5.2.1.1 Rising incidence of cancer and infectious diseases 57
TABLE 2 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION) 57
TABLE 3 PROJECTED INCREASE IN GLOBAL NUMBER OF CANCER PATIENTS, 2018 VS. 2020 VS. 2040 58
5.2.1.2 Growing demand for digital pathology 59
5.2.1.3 Increasing healthcare expenditure 60
FIGURE 20 CURRENT HEALTH EXPENDITURE PER CAPITA 60
FIGURE 21 CURRENT HEALTH EXPENDITURE (% OF GDP) 60
5.2.1.4 Growing availability of reimbursements 61
5.2.1.5 Rising establishment of private diagnostics centers 62
5.2.2 RESTRAINTS 62
5.2.2.1 High cost of tissue diagnostic systems 62
5.2.2.2 Stringent regulatory requirements 63
5.2.3 OPPORTUNITIES 63
5.2.3.1 High growth potential of emerging economies 63
FIGURE 22 GROWTH IN CURRENT HEALTHCARE EXPENDITURE IN BRICS COUNTRIES, 2012–2020 64
5.2.3.2 Growing preference for personalized medicines 64
FIGURE 23 PERSONALIZED MEDICINES APPROVED BY FDA (%), 2015–2022 65
5.2.3.3 Increasing number of clinical trials for cancer therapeutics 65
5.2.4 CHALLENGES 66
5.2.4.1 Shortage of skilled professionals 66
5.2.4.2 Availability of refurbished products 66
5.2.4.3 Inadequate standardization for TDx 67
5.2.5 INDUSTRY TRENDS 67
5.2.5.1 Increasing number of reagent rental agreements 67
5.2.5.2 Growing usage of AI in histopathology 68
5.3 VALUE CHAIN ANALYSIS 68
FIGURE 24 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASE 69
5.4 SUPPLY CHAIN ANALYSIS 70
FIGURE 25 DIRECT DISTRIBUTION—PREFERRED STRATEGY FOR PROMINENT COMPANIES 70
5.5 TECHNOLOGY ANALYSIS 71
5.6 PORTER’S FIVE FORCES ANALYSIS 71
5.6.1 THREAT OF NEW ENTRANTS 72
5.6.2 BARGAINING POWER OF BUYERS 72
5.6.3 BARGAINING POWER OF SUPPLIERS 72
5.6.4 THREAT OF SUBSTITUTES 72
5.6.5 INTENSITY OF COMPETITIVE RIVALRY 72
5.7 KEY STAKEHOLDERS AND BUYING CRITERIA 73
5.7.1 KEY STAKEHOLDERS IN BUYING PROCESS 73
FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USERS 73
TABLE 4 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE END USERS (%) 73
5.7.2 BUYING CRITERIA 74
FIGURE 27 KEY BUYING CRITERIA FOR TOP THREE END USERS 74
TABLE 5 KEY BUYING CRITERIA FOR END USERS 74
5.8 REGULATORY LANDSCAPE 74
TABLE 6 INDICATIVE LIST OF REGULATORY AUTHORITIES IN TISSUE DIAGNOSTICS MARKET 74
5.9 PATENT ANALYSIS 77
5.10 KEY CONFERENCES AND EVENTS 78
TABLE 7 LIST OF CONFERENCES & EVENTS (2023−2024) 78
5.11 PRICING ANALYSIS 80
TABLE 8 PRICE RANGE FOR TISSUE DIAGNOSTICS 80
5.12 TRADE ANALYSIS 81
TABLE 9 IMPORT DATA FOR MICROTOMES, PARTS, AND ACCESSORIES OF INSTRUMENTS AND APPARATUS FOR PHYSICAL/CHEMICAL ANALYSIS, BY COUNTRY, 2018–2022 (USD MILLION) 81
TABLE 10 EXPORT DATA FOR MICROTOMES, PARTS, AND ACCESSORIES OF INSTRUMENTS AND APPARATUS FOR PHYSICAL/CHEMICAL ANALYSIS, BY COUNTRY, 2018–2022 (USD MILLION) 81
5.13 ECOSYSTEM MARKET/MAP 82
TABLE 11 TISSUE DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM 82
FIGURE 28 KEY PLAYERS OPERATING IN TISSUE DIAGNOSTICS MARKET 83
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 83
6 TISSUE DIAGNOSTICS MARKET, BY PRODUCT 84
6.1 INTRODUCTION 85
TABLE 12 TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 85
6.2 CONSUMABLES 85
TABLE 13 TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION) 86
TABLE 14 TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY REGION, 2021–2028 (USD MILLION) 86
6.2.1 ANTIBODIES 86
6.2.1.1 Rising prevalence of infectious diseases to drive market 86
TABLE 15 TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY REGION, 2021–2028 (USD MILLION) 87
6.2.2 KITS 87
6.2.2.1 Optimized sensitivity and versatility to boost demand 87
TABLE 16 TISSUE DIAGNOSTICS MARKET FOR KITS, BY REGION, 2021–2028 (USD MILLION) 88
6.2.3 REAGENTS 88
6.2.3.1 Rising uptake in IHC and FISH procedures to support market growth 88
TABLE 17 TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY REGION, 2021–2028 (USD MILLION) 89
6.2.4 PROBES 89
6.2.4.1 Utilization in fluorescence microscopy applications to boost demand 89
TABLE 18 TISSUE DIAGNOSTICS MARKET FOR PROBES, BY REGION, 2021–2028 (USD MILLION) 90
6.3 INSTRUMENTS 90
TABLE 19 TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION) 90
TABLE 20 TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2021–2028 (USD MILLION) 91
6.3.1 SLIDE-STAINING SYSTEMS 91
6.3.1.1 Development of high-throughput staining systems to drive market 91
TABLE 21 KEY MANUFACTURERS OF AUTOMATED SLIDE STAINERS 92
TABLE 22 TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY REGION, 2021–2028 (USD MILLION) 92
6.3.2 SCANNERS 93
6.3.2.1 Rising use of multiplexed IHC scanners to drive market 93
TABLE 23 TISSUE DIAGNOSTICS MARKET FOR SCANNERS, BY REGION, 2021–2028 (USD MILLION) 93
6.3.3 TISSUE-PROCESSING SYSTEMS 93
6.3.3.1 Rising need for automation to support market growth 93
TABLE 24 TISSUE DIAGNOSTICS MARKET FOR TISSUE-PROCESSING SYSTEMS, BY REGION, 2021–2028 (USD MILLION) 94
6.3.4 OTHER INSTRUMENTS 94
TABLE 25 TISSUE DIAGNOSTICS MARKET FOR OTHER INSTRUMENTS, BY REGION, 2021–2028 (USD MILLION) 95
7 TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY 96
7.1 INTRODUCTION 97
TABLE 26 TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 97
7.2 IMMUNOHISTOCHEMISTRY 97
7.2.1 RISING UPTAKE OF IHC KITS FOR DIAGNOSTIC APPLICATIONS TO FUEL MARKET 97
TABLE 27 TISSUE DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY REGION, 2021–2028 (USD MILLION) 98
7.3 IN SITU HYBRIDIZATION 99
7.3.1 ABILITY TO DETECT SPECIFIC RNA AND DNA SEQUENCES TO BOOST DEMAND 99
TABLE 28 TISSUE DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2021–2028 (USD MILLION) 100
7.4 DIGITAL PATHOLOGY & WORKFLOW MANAGEMENT 100
7.4.1 RISING NEED FOR ANALYSIS AND SEAMLESS MANAGEMENT TO SUPPORT MARKET GROWTH 100
TABLE 29 TISSUE DIAGNOSTICS MARKET FOR DIGITAL PATHOLOGY & WORKFLOW MANAGEMENT, BY REGION, 2021–2028 (USD MILLION) 101
7.5 SPECIAL STAINING 101
7.5.1 UTILIZATION IN CANCER DIAGNOSTICS TO BOOST DEMAND 101
TABLE 30 TISSUE DIAGNOSTICS MARKET FOR SPECIAL STAINING, BY REGION, 2021–2028 (USD MILLION) 101
8 TISSUE DIAGNOSTICS MARKET, BY DISEASE TYPE 102
8.1 INTRODUCTION 103
TABLE 31 GLOBAL CANCER INCIDENCE, 2020 VS. 2040 103
TABLE 32 TISSUE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 104
8.2 BREAST CANCER 104
8.2.1 RISING UPTAKE OF HER2 TESTS FOR CANCER DIAGNOSIS TO DRIVE MARKET 104
TABLE 33 BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2040 105
FIGURE 29 ARTICLES PUBLISHED ON BREAST CANCER TISSUE DIAGNOSTICS, 2011–2021 105
TABLE 34 TISSUE DIAGNOSTICS MARKET FOR BREAST CANCER, BY REGION, 2021–2028 (USD MILLION) 105
8.3 GASTRIC CANCER 106
8.3.1 RISING INCIDENCE OF GASTROINTESTINAL CANCER TO BOOST DEMAND 106
TABLE 35 COLON CANCER INCIDENCE, BY REGION, 2020 VS. 2040 106
TABLE 36 TISSUE DIAGNOSTICS MARKET FOR GASTRIC CANCER, BY REGION, 2021–2028 (USD MILLION) 107
8.4 LYMPHOMA 107
8.4.1 RISING INCIDENCE OF NON-HODGKIN’S LYMPHOMA IN ADULTS TO SUPPORT MARKET GROWTH 107
TABLE 37 HODGKIN LYMPHOMA INCIDENCE, BY REGION, 2020 VS. 2040 108
TABLE 38 NON-HODGKIN LYMPHOMA INCIDENCE, BY REGION, 2020 VS. 2040 108
TABLE 39 TISSUE DIAGNOSTICS MARKET FOR LYMPHOMA, BY REGION, 2021–2028 (USD MILLION) 108
8.5 PROSTATE CANCER 108
8.5.1 RISING UPTAKE OF ISH TESTS FOR DIAGNOSIS TO FUEL MARKET 108
TABLE 40 PROSTATE CANCER INCIDENCE, BY REGION, 2020 VS. 2040 109
TABLE 41 TISSUE DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY REGION, 2021–2028 (USD MILLION) 109
8.6 NON-SMALL CELL LUNG CANCER 109
8.6.1 GROWING FOCUS ON DEVELOPING COMPANION DIAGNOSTIC TESTS TO DRIVE MARKET 109
TABLE 42 TISSUE DIAGNOSTICS MARKET FOR NON-SMALL CELL LUNG CANCER, BY REGION, 2021–2028 (USD MILLION) 110
8.7 OTHER DISEASE TYPES 110
TABLE 43 TISSUE DIAGNOSTICS MARKET FOR OTHER DISEASE TYPES, BY REGION, 2021–2028 (USD MILLION) 111
9 TISSUE DIAGNOSTICS MARKET, BY END USER 112
9.1 INTRODUCTION 113
TABLE 44 TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 113
9.2 HOSPITALS 113
9.2.1 ABILITY TO OFFER ADVANCED EQUIPMENT & INFRASTRUCTURE TO DRIVE MARKET 113
TABLE 45 TISSUE DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2021–2028 (USD MILLION) 114
9.3 RESEARCH LABORATORIES 114
9.3.1 RISING DEMAND OF SPECIALTY TESTS TO DRIVE MARKET 114
TABLE 46 TISSUE DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, BY REGION, 2021–2028 (USD MILLION) 115
9.4 PHARMACEUTICAL COMPANIES 115
9.4.1 INCREASING R&D ACTIVITIES FOR DISEASE DIAGNOSTICS TO DRIVE MARKET 115
TABLE 47 TISSUE DIAGNOSTICS MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2021–2028 (USD MILLION) 115
9.5 CONTRACT RESEARCH ORGANIZATIONS 116
9.5.1 OUTSOURCING OF R&D ACTIVITIES TO SUPPORT MARKET GROWTH 116
TABLE 48 CONTRACT RESEARCH ORGANIZATIONS FOR ONCOLOGY DIAGNOSTICS 116
TABLE 49 TISSUE DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION) 116
9.6 OTHER END USERS 117
TABLE 50 TISSUE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION) 117
10 TISSUE DIAGNOSTICS MARKET, BY REGION 118
10.1 INTRODUCTION 119
TABLE 51 TISSUE DIAGNOSTICS MARKET, BY REGION, 2021–2028 (USD MILLION) 119
10.2 NORTH AMERICA 119
FIGURE 30 TISSUE DIAGNOSTICS MARKET: NORTH AMERICA SNAPSHOT 120
TABLE 52 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 53 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 121
TABLE 54 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION) 121
TABLE 55 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION) 122
TABLE 56 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 122
TABLE 57 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 123
TABLE 58 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 123
10.2.1 US 123
10.2.1.1 High healthcare expenditure to drive market 123
TABLE 59 US CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 124
TABLE 60 US: KEY MACROINDICATORS 124
TABLE 61 LIST OF US FDA-APPROVED PRODUCTS FOR TISSUE DIAGNOSTICS 125
TABLE 62 US: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 125
TABLE 63 US: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION) 126
TABLE 64 US: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION) 126
TABLE 65 US: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 126
TABLE 66 US: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 127
10.2.2 CANADA 127
10.2.2.1 High prevalence of cancer to support market growth 127
TABLE 67 CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 127
TABLE 68 CANADA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 128
TABLE 69 CANADA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION) 129
TABLE 70 CANADA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION) 129
TABLE 71 CANADA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 129
TABLE 72 CANADA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 130
10.2.3 NORTH AMERICA: RECESSION IMPACT 130
10.3 EUROPE 131
TABLE 73 EUROPE: TISSUE DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 74 EUROPE: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 132
TABLE 75 EUROPE: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION) 132
TABLE 76 EUROPE: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION) 132
TABLE 77 EUROPE: TISSUE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 133
TABLE 78 EUROPE: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 133
TABLE 79 EUROPE: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 134
10.3.1 GERMANY 134
10.3.1.1 Availability of reimbursements for colorectal cancer screening procedures to support market growth 134
TABLE 80 GERMANY: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040 134
TABLE 81 GERMANY: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 135
TABLE 82 GERMANY: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION) 135
TABLE 83 GERMANY: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION) 135
TABLE 84 GERMANY: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 136
TABLE 85 GERMANY: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION 136
10.3.2 UK 136
10.3.2.1 Rising investments in cancer research to propel market 136
TABLE 86 UK: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 137
TABLE 87 UK: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION) 138
TABLE 88 UK: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION) 138
TABLE 89 UK: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 138
TABLE 90 UK: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 139
10.3.3 FRANCE 139
10.3.3.1 Growing focus on early disease diagnosis to boost demand 139
TABLE 91 FRANCE: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040 139
TABLE 92 FRANCE: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 140
TABLE 93 FRANCE: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION) 140
TABLE 94 FRANCE: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION) 140
TABLE 95 FRANCE: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 141
TABLE 96 FRANCE: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 141
10.3.4 ITALY 141
10.3.4.1 High incidence of cancer and geriatric population to support market growth 141
TABLE 97 ITALY: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040 142
TABLE 98 ITALY: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 142
TABLE 99 ITALY: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION) 143
TABLE 100 ITALY: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION) 143
TABLE 101 ITALY: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 143
TABLE 102 ITALY: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 144
10.3.5 SPAIN 144
10.3.5.1 High incidence of chronic diseases to drive market 144
TABLE 103 SPAIN: CANCER INCIDENCE, BY TYPE, 2020 VS. 2025 144
TABLE 104 SPAIN: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 145
TABLE 105 SPAIN: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION) 145
TABLE 106 SPAIN: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION) 145
TABLE 107 SPAIN: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 146
TABLE 108 SPAIN: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 146
10.3.6 REST OF EUROPE 146
TABLE 109 REST OF EUROPE: CANCER INCIDENCE, 2020 VS. 2025 147
TABLE 110 REST OF EUROPE: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 147
TABLE 111 REST OF EUROPE: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION) 148
TABLE 112 REST OF EUROPE: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION) 148
TABLE 113 REST OF EUROPE: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 148
TABLE 114 REST OF EUROPE: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 149
10.3.7 EUROPE: RECESSION IMPACT 149
10.4 ASIA PACIFIC 150
FIGURE 31 TISSUE DIAGNOSTICS MARKET: ASIA PACIFIC SNAPSHOT 151
TABLE 115 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 151
TABLE 116 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 152
TABLE 117 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION) 152
TABLE 118 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION) 152
TABLE 119 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2021–2028 (USD MILLION) 153
TABLE 120 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 153
TABLE 121 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 154
10.4.1 CHINA 154
10.4.1.1 Rising incidence of chronic & infectious diseases to propel market 154
TABLE 122 CANCER INCIDENCE, BY CANCER TYPE (CHINA), 2020 VS. 2025 154
TABLE 123 CHINA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 155
TABLE 124 CHINA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION) 155
TABLE 125 CHINA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION) 155
TABLE 126 CHINA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 156
TABLE 127 CHINA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 156
10.4.2 JAPAN 156
10.4.2.1 Development of advanced diagnostic products to fuel market 156
TABLE 128 CANCER INCIDENCE, BY CANCER TYPE (JAPAN), 2020 VS. 2040 156
TABLE 129 JAPAN: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 157
TABLE 130 JAPAN: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION) 157
TABLE 131 JAPAN: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION) 158
TABLE 132 JAPAN: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 158
TABLE 133 JAPAN: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 158
10.4.3 INDIA 159
10.4.3.1 Rising establishment of diagnostic centers to drive market 159
TABLE 134 INDIA: CANCER INCIDENCE, BY TYPE, 2020 VS. 2025 159
TABLE 135 INDIA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 160
TABLE 136 INDIA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION) 160
TABLE 137 INDIA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION) 160
TABLE 138 INDIA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 161
TABLE 139 INDIA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 161
10.4.4 REST OF ASIA PACIFIC 161
TABLE 140 REST OF ASIA PACIFIC: CANCER INCIDENCE, 2020 VS. 2040 162
TABLE 141 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 162
TABLE 142 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION) 163
TABLE 143 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION) 163
TABLE 144 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 163
TABLE 145 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 164
10.4.5 ASIA PACIFIC: RECESSION IMPACT 164
10.5 REST OF THE WORLD 164
TABLE 146 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET, BY REGION, 2021–2028 (USD MILLION) 165
TABLE 147 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 165
TABLE 148 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION) 165
TABLE 149 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION) 166
TABLE 150 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 166
TABLE 151 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 167
TABLE 152 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 167
10.5.1 LATIN AMERICA 167
10.5.1.1 Rising number of cancer screening programs to drive market 167
TABLE 153 LATIN AMERICA: CANCER INCIDENCE, 2020 VS. 2025 168
TABLE 154 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 168
TABLE 155 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION) 169
TABLE 156 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION) 169
TABLE 157 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 169
TABLE 158 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 170
10.5.2 MIDDLE EAST & AFRICA 170
10.5.2.1 Improvements in healthcare infrastructure to support market growth 170
TABLE 159 CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2025 170
TABLE 160 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 171
TABLE 161 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION) 171
TABLE 162 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION) 172
TABLE 163 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 172
TABLE 164 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 173
10.5.3 REST OF THE WORLD: RECESSION IMPACT 173
11 COMPETITIVE LANDSCAPE 174
11.1 OVERVIEW 174
11.2 KEY PLAYER STRATEGIES 174
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY MARKET PLAYERS 174
TABLE 165 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN TISSUE DIAGNOSTICS MARKET 175
11.3 REVENUE ANALYSIS OF TOP MARKET PLAYERS 176
FIGURE 32 REVENUE ANALYSIS OF KEY PLAYERS IN TISSUE DIAGNOSTICS MARKET 176
11.4 MARKET SHARE ANALYSIS 177
TABLE 166 TISSUE DIAGNOSTICS MARKET: INTENSITY OF COMPETITIVE RIVALRY 177
FIGURE 33 TISSUE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER (2022) 178
11.5 COMPANY EVALUATION MATRIX 179
11.5.1 STARS 179
11.5.2 EMERGING LEADERS 179
11.5.3 PERVASIVE PLAYERS 179
11.5.4 PARTICIPANTS 179
FIGURE 34 TISSUE DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX 180
11.5.5 COMPETITIVE BENCHMARKING OF KEY PLAYERS 181
TABLE 167 COMPANY FOOTPRINT 181
11.5.6 PRODUCT FOOTPRINT 182
11.5.7 REGIONAL FOOTPRINT 183
11.6 START-UP/SME EVALUATION MATRIX 184
11.6.1 PROGRESSIVE COMPANIES 184
11.6.2 RESPONSIVE COMPANIES 184
11.6.3 DYNAMIC COMPANIES 184
11.6.4 STARTING BLOCKS 184
FIGURE 35 TISSUE DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES 185
11.7 COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS 186
TABLE 168 TISSUE DIAGNOSTICS MARKET: KEY STARTUPS/SMES 186
11.8 COMPETITIVE SCENARIOS AND TRENDS 187
11.8.1 PRODUCT LAUNCHES & APPROVALS 187
TABLE 169 TISSUE DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS (JANUARY 2020−OCTOBER 2023) 187
11.8.2 DEALS 188
TABLE 170 TISSUE DIAGNOSTICS MARKET: DEALS (JANUARY 2020−OCTOBER 2023) 188
11.8.3 OTHER DEVELOPMENTS 189
TABLE 171 TISSUE DIAGNOSTIC MARKET: OTHER DEVELOPMENTS (JANUARY 2020−OCTOBER 2023) 189
12 COMPANY PROFILES 190
(Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) *
12.1 KEY PLAYERS 190
12.1.1 F. HOFFMANN-LA ROCHE LTD. 190
TABLE 172 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW 190
FIGURE 36 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022) 191
12.1.2 DANAHER CORPORATION 197
TABLE 173 DANAHER CORPORATION: BUSINESS OVERVIEW 197
FIGURE 37 DANAHER CORPORATION: COMPANY SNAPSHOT (2022) 198
12.1.3 PHC HOLDINGS CORPORATION 202
TABLE 174 PHC HOLDINGS CORPORATION: BUSINESS OVERVIEW 202
FIGURE 38 PHC HOLDINGS CORPORATION: COMPANY SNAPSHOT (2022) 203
12.1.4 THERMO FISHER SCIENTIFIC INC. 206
TABLE 175 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW 206
FIGURE 39 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022) 207
12.1.5 ABBOTT 210
TABLE 176 ABBOTT: BUSINESS OVERVIEW 210
FIGURE 40 ABBOTT: COMPANY SNAPSHOT (2022) 211
12.1.6 AGILENT TECHNOLOGIES, INC. 213
TABLE 177 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW 213
FIGURE 41 AGILENT TECHNOLOGIES INC.: COMPANY SNAPSHOT (2022) 214
12.1.7 MERCK KGAA 218
TABLE 178 MERCK KGAA: BUSINESS OVERVIEW 218
FIGURE 42 MERCK KGAA: COMPANY SNAPSHOT (2022) 219
12.1.8 SAKURA FINETEK JAPAN CO., LTD. 221
TABLE 179 SAKURA FINETEK JAPAN CO., LTD.: BUSINESS OVERVIEW 221
12.1.9 ABCAM PLC 224
TABLE 180 ABCAM PLC.: BUSINESS OVERVIEW 224
FIGURE 43 ABCAM PLC. COMPANY SNAPSHOT (2022) 225
12.1.10 BECTON, DICKINSON AND COMPANY (BD) 227
TABLE 181 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 227
FIGURE 44 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022) 228
12.1.11 BIO SB 229
TABLE 182 BIO SB: BUSINESS OVERVIEW 229
12.1.12 BIOGENEX 230
TABLE 183 BIOGENEX: BUSINESS OVERVIEW 230
12.1.13 CELL SIGNALING TECHNOLOGY, INC. 232
TABLE 184 CELL SIGNALING TECHNOLOGY, INC.: BUSINESS OVERVIEW 232
12.1.14 HISTO-LINE LABORATORIES 233
TABLE 185 HISTO-LINE LABORATORIES: BUSINESS OVERVIEW 233
12.1.15 SLEE MEDICAL GMBH 236
TABLE 186 SLEE MEDICAL GMBH: BUSINESS OVERVIEW 236
12.1.16 CELLPATH LTD. 238
TABLE 187 CELLPATH LTD.: BUSINESS OVERVIEW 238
12.2 OTHER PLAYERS 239
12.2.1 AMOS SCIENTIFIC PTY LTD. 239
12.2.2 JINHUA YIDI MEDICAL APPLIANCE CO., LTD. 240
12.2.3 MEDITE MEDICAL GMBH 241
12.2.4 DIAPATH S.P.A. 242
12.2.5 KFBIO KONFOONG BIOINFORMATION TECH CO., LTD 243
12.2.6 DIAGNOSTIC BIOSYSTEMS INC. 244
12.2.7 3DHISTECH LTD. 245
12.2.8 RWD LIFE SCIENCE CO., LTD. 246
12.2.9 DAKEWE 247
12.2.10 SYSMEX CORPORATION 248
12.2.11 ENZO LIFE SCIENCES, INC. 249
12.2.12 BIOCARE MEDICAL, LLC. 250
12.2.13 MILESTONE MEDICAL 251
12.2.14 BIO-OPTICA MILANO SPA 252
*Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.
13 APPENDIX 253
13.1 DISCUSSION GUIDE 253
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 257
13.3 CUSTOMIZATION OPTIONS 259
13.4 RELATED REPORTS 259
13.5 AUTHOR DETAILS 261